About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingNCT06778616

Frequency and Predictors of Recurrent SBP in Cirrhotic Patients in Al Rajhi University Hospital

* Assess the frequency of recurrent SBP in ascitic cirrhotic patients. * Determine the predictive factors of recurrence after the first episode of SBP in ascitic cirrhotic patients

Lead sponsor: Assiut University•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Asmaa M Hussein, MSc

CONTACT

00201070041233 asmaamoussa299@gamil.com

Marwa A Ahmed, MD

CONTACT

00201155544090 Marwamakhlof088@gmail.com

Sponsors

Lead Sponsor

Assiut University

Spontaneous bacterial peritonitis (SBP) is a common complication in cirrhotic patients. The prevalence of SBP in hospitalized patients and the mortality rate were reported to be 10%-30% and 30%-50%, respectively. SBP has been considered a life-threatening infection that requires a prompt diagnosis and treatment.

Age

0 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Any cirrhotic patient above the age of 18 years old of both sexes, having a first episode of SBP will be included in our study.
•1. The diagnosis of cirrhosis was based on clinical manifestation (ascites, splenomegaly, lower limb edema and/or esophageal varices by upper gastrointestinal endoscopy), laboratory findings and radiological (abdominal ultrasonography), or liver histology.
•2. The diagnosis of SBP was based on a neutrophil cell count of 250 cell or more per mm3 with or without culture positivity of ascitic fluid, in the absence of hemorrhagic ascites and secondary peritonitis.

Exclusion Criteria

•Any patient with one or more of the following criteria will be excluded:
•1. Patients with bacterial ascites defined by a positive culture of ascitic fluid associated with a neutrophil cell count less than 250 cell per mm3 in the ascitic fluid.
•2. Patients presenting with empyema or bacterial peritonitis secondary to an intra-abdominal organ perforation or surgical operation

Related studies

Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis

NCT06026267 · Liver Cirrhosis, Spontaneous Bacterial Peritonitis

RECRUITINGPhase 3

Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

NCT04168099 · Spontaneous Bacterial Peritonitis

Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis

NCT04153604 · Cirrhosis, Spontaneous Bacterial Peritonitis

Not Yet Recruiting

Prediction of SBP in Cirrhotic Patients by Platlet Count, Na and AlBl Index.

NCT07116369 · Spontaneous Bacterial Peritonitis

Not Yet RecruitingNA

Early Ascitis Parencentesis in SBP

NCT06679842 · Cirrhosis, Spontaneous Bacterial Peritonitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 16, 2025Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment101

Start dateFeb 2025

Last updatedJan 16, 2025

Condition

Spontaneous Bacterial Peritonitis

Locations shown

Assiut Faculty of Medicine

Asyut, Asyut Governorate

Assiut University

Asyut, Asyut Governorate

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions